Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.4 HKD | 0.00% | +3.45% | -19.76% |
04-25 | Simcere Pharmaceutical’ Profit Down 23% in 2023 | MT |
04-10 | Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 52% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.76% | 1.77B | - | ||
+20.37% | 43.75B | B- | ||
+27.47% | 22.06B | B+ | ||
+13.30% | 14.46B | - | ||
+13.03% | 13.62B | B+ | ||
+38.31% | 11.61B | B | ||
-9.54% | 6.9B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+9.64% | 5.32B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2096 Stock
- Ratings Simcere Pharmaceutical Group Limited